title: Efalizumab-induced severe thrombocytopenia can be resolved.
abstract: Efalizumab is a monoclonal a humanized recombinant IgG1 monoclonal antibody which targets the CD11a, the alpha-subunit of LFA-1 (lymphocyte function-associated antigen-1). It acts by blocking the T-lymphocyte pathogenetic mechanisms of psoriasis. Thrombocytopenia is an adverse event that occurs during therapy. Thrombocytopenia can be mild and can occur quite early during treatment, together with leukocytosis. Both adverse events tend to normalize with ongoing therapy, or, in cases worsening, with therapy suspension. There have been multiple reports of thrombocytopenia associated with efalizumab therapy for the treatment of psoriasis. The general recommendation is to check platelet counts monthly for the first 3 months of efalizumab therapy, then every 3 months for the duration of therapy. According to our experience on a wide range of patients, it is useful to check platelets every month for the first 6 months of therapy. We report a case of efalizumab-associated thrombocytopenia that occurred after 16 weeks of therapy together with clinical worsening of skin lesions. The peculiarity of our case is the absence of signs and symptoms linked to thrombocytopenia and the quick return to normal platelet count without corticosteroid therapy.
authors.affiliation: University Unit of Dermatology and Physiotherapy, School of Medicine, University of Florence, Florence, Italy.
authors.forename: Francesca
authors.initials: F
authors.lastname: Prignano
authors.forename: F
authors.initials: F
authors.lastname: Zanieri
authors.forename: S
authors.initials: S
authors.lastname: Mokhtarzadeh
authors.forename: T
authors.initials: T
authors.lastname: Lotti
references.citation: JAMA. 2003 Dec 17;290(23):3073-80
references.pmid: 14679270
references.citation: Br J Dermatol. 2008 May;158(5):1107-16
references.pmid: 18373710
references.citation: Drug Saf. 2004;27(15):1243-52
references.pmid: 15588119
references.citation: Clin Exp Dermatol. 2001 Jun;26(4):314-20
references.pmid: 11422182
references.citation: J Am Acad Dermatol. 2005 Mar;52(3 Pt 1):425-33
references.pmid: 15761420
references.citation: Arch Dermatol. 2005 Jan;141(1):31-8
references.pmid: 15655139
references.citation: J Am Acad Dermatol. 1984 Nov;11(5 Pt 2):937-47
references.pmid: 6389615
references.citation: J Am Acad Dermatol. 2007 Oct;57(4):707-10
references.pmid: 17637485
references.citation: J Dermatolog Treat. 2006;17(5):288-93
references.pmid: 17092859
references.citation: Ann Rheum Dis. 2005 Mar;64 Suppl 2:ii30-6
references.pmid: 15708932
references.citation: Expert Opin Drug Saf. 2006 Mar;5(2):197-209
references.pmid: 16503742
references.citation: Dermatol Ther. 2008 Oct;21 Suppl 2:S25-9
references.pmid: 18837730
references.citation: J Drugs Dermatol. 2004 Nov-Dec;3(6):614-24
references.pmid: 15624744